Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XRTX
stocks logo

XRTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
--
--
-0.290
-38.3%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for XORTX Therapeutics Inc. (XRTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -23.50%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.50%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for XORTX Therapeutics Inc (XRTX.O) is -1.29, compared to its 5-year average forward P/E of -2.15. For a more detailed relative valuation and DCF analysis to assess XORTX Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.15
Current PE
-1.29
Overvalued PE
-0.23
Undervalued PE
-4.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.25
Undervalued EV/EBITDA
-1.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.44
Current PS
0.00
Overvalued PS
1.50
Undervalued PS
-0.62
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XRTX News & Events

Events Timeline

(ET)
2025-10-21
08:15:11
Xortx Therapeutics sets price for 1.75 million shares at $0.63 in direct registered offering
select
2025-10-17 (ET)
2025-10-17
07:03:36
Xortx to Purchase Renal Anti-Fibrotic Therapeutic Program from Vectus for $3 Million
select
2025-09-03 (ET)
2025-09-03
07:06:20
Xortx Therapeutics Begins IND Preparation for XORLO in Gout Treatment Program
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-03Benzinga
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.

  • Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.

  • Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.

  • Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.

[object Object]
Preview
7.0
10-21SeekingAlpha
XORTX Therapeutics Secures 180-Day Extension from Nasdaq to Meet $1.00 Bid Price Requirement

  • Extension Granted: XORTX Therapeutics has received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, now due by April 13, 2026.

  • Compliance Efforts: The company must ensure its shares close at or above $1.00 for ten consecutive business days to avoid delisting, while its listing on the TSX venture exchange remains unaffected.

[object Object]
Preview
7.0
10-21Newsfilter
XORTX Receives Nasdaq Notification Concerning Minimum Bid Price Shortfall

  • Compliance Notification: XORTX Therapeutics Inc. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares have been below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance.

  • Company Overview: XORTX is focused on developing therapies for progressive kidney disease and gout, with several products in clinical development, including treatments for gout and acute kidney injury. The company is committed to improving the health of individuals with these conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is XORTX Therapeutics Inc (XRTX) stock price today?

The current price of XRTX is 0.6311 USD — it has decreased -0.47 % in the last trading day.

arrow icon

What is XORTX Therapeutics Inc (XRTX)'s business?

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

arrow icon

What is the price predicton of XRTX Stock?

Wall Street analysts forecast XRTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRTX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is XORTX Therapeutics Inc (XRTX)'s revenue for the last quarter?

XORTX Therapeutics Inc revenue for the last quarter amounts to -716.20K USD, decreased -18.13 % YoY.

arrow icon

What is XORTX Therapeutics Inc (XRTX)'s earnings per share (EPS) for the last quarter?

XORTX Therapeutics Inc. EPS for the last quarter amounts to -635103.00 USD, decreased -18.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for XORTX Therapeutics Inc (XRTX)'s fundamentals?

The market is revising No Change the revenue expectations for XORTX Therapeutics Inc. (XRTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -23.50%.
arrow icon

How many employees does XORTX Therapeutics Inc (XRTX). have?

XORTX Therapeutics Inc (XRTX) has 2 emplpoyees as of December 05 2025.

arrow icon

What is XORTX Therapeutics Inc (XRTX) market cap?

Today XRTX has the market capitalization of 4.39M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free